CSInc. updates on CS-1103 at Behavioral Healthcare Symposium organized by CA Hospital Association

Cambridge, MA | December 2022

Shekar Shetty, Clear Scientific Inc.’s CEO, gave an update on our first- in-class therapeutic agent CS-1103 to treat methamphetamine overdose at the Behavioral Health Care Symposium entitled “Hope for treating Methamphetamine Use Disorder”, organized by the California Hospital Association at Riverside CA. CS-1103 is designed to lower the level of methamphetamine in the human body and rapidly resolve its toxic effects. Remove the Cause Remove the EffectTM is the hallmark of Clear Scientific’s therapeutic approach.